Aviceda Glycotech

Aviceda Glycotech was an oncology-focused biotechnology spin-out formed from Aviceda Therapeutics and Queen’s University Belfast to develop next-generation glyco-immune therapeutics using glycobiology. The company’s approach centered on Aviceda’s HALOS platform, which uses high-affinity ligands of Siglecs to modulate innate immune checkpoints and advance immuno-oncology research. Publicly available descriptions characterized the company as a private IND-stage biotech based in Belfast and focused on cancer and immunology. However, the UK legal entity AVICEDA GLYCOTECH LTD was dissolved on December 9, 2025, indicating the named company is no longer an active standalone company. The broader Aviceda organization remains active through Aviceda Therapeutics, which continues developing glyco-immune checkpoint therapeutics.